Active Biotech AB (publ)
SSE:ACTI.ST
0.69 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Active Biotech AB (publ) |
Symbool | ACTI.ST |
Munteenheid | SEK |
Prijs | 0.685 |
Beurswaarde | 259,210,850 |
Dividendpercentage | 0% |
52-weken bereik | 0.401 - 1.478 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Helen Tuvesson Ph.D. |
Website | https://www.activebiotech.com |
An error occurred while fetching data.
Over Active Biotech AB (publ)
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)